Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.17B | 164.49M | 205.99M | 186.42M | 292.68M |
| Total Depreciation and Amortization | 14.48M | 13.90M | 13.55M | 13.51M | 13.80M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.74B | 176.60M | 148.69M | 36.78M | 223.28M |
| Change in Net Operating Assets | -103.15M | -28.27M | -297.73M | -73.15M | -232.91M |
| Cash from Operations | 340.99M | 326.72M | 70.50M | 163.56M | 296.86M |
| Capital Expenditure | -69.83M | -34.68M | -21.83M | -23.29M | -12.14M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -241.91M | -328.78M | -3.71M | -13.87M | 513.25M |
| Cash from Investing | -311.74M | -363.46M | -25.54M | -37.17M | 501.11M |
| Total Debt Issued | -- | -- | -- | -680.00K | 646.37M |
| Total Debt Repaid | -- | -- | -- | -52.25M | -1.14B |
| Issuance of Common Stock | 15.47M | 33.56M | 13.16M | 41.70M | 77.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.89M | 2.68M | 2.56M | 56.55M | -3.82M |
| Cash from Financing | 18.35M | 36.24M | 15.71M | 45.32M | -420.09M |
| Foreign Exchange rate Adjustments | -1.26M | -2.45M | -7.06M | -5.70M | -927.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.34M | -2.94M | 53.61M | 166.01M | 376.94M |